2024
Effects of anhedonia on health-related quality of life and functional outcomes in major depressive disorder: A systematic review and meta-analysis
Wong S, Le G, Phan L, Rhee T, Ho R, Meshkat S, Teopiz K, Kwan A, Mansur R, Rosenblat J, McIntyre R. Effects of anhedonia on health-related quality of life and functional outcomes in major depressive disorder: A systematic review and meta-analysis. Journal Of Affective Disorders 2024, 356: 684-698. PMID: 38657767, DOI: 10.1016/j.jad.2024.04.086.Peer-Reviewed Original ResearchConceptsMajor depressive disorderSnaith-Hamilton Pleasure ScaleEffect of anhedoniaDepressive disorderAssociated with depressive symptom severityGroup of mood disordersSocial functioning deficitsSymptoms of anhedoniaDepressive symptom severitySelf-report measuresAnticipatory anhedoniaReward valuationConsummatory anhedoniaReward learningPleasure ScaleInvestigated anhedoniaMood disordersSymptom domainsAnhedoniaHealth-related quality of lifeSymptom severityFunctional outcomesHealth-related qualityQuality of lifeFunctional impairmentSpectral signatures of psilocybin, lysergic acid diethylamide (LSD) and ketamine in healthy volunteers and persons with major depressive disorder and treatment-resistant depression: A systematic review
Le G, Wong S, Badulescu S, Au H, Di Vincenzo J, Gill H, Phan L, Rhee T, Ho R, Teopiz K, Kwan A, Rosenblat J, Mansur R, McIntyre R. Spectral signatures of psilocybin, lysergic acid diethylamide (LSD) and ketamine in healthy volunteers and persons with major depressive disorder and treatment-resistant depression: A systematic review. Journal Of Affective Disorders 2024, 355: 342-354. PMID: 38570038, DOI: 10.1016/j.jad.2024.03.165.Peer-Reviewed Original ResearchMeSH KeywordsDepressionDepressive Disorder, MajorHallucinogensHealthy VolunteersHumansKetamineLysergic Acid DiethylamidePsilocybinConceptsTreatment-resistant depressionLysergic acid diethylamideSerotonergic psychedelicsDepressive disorderHealthy controlsTheta powerHealthy volunteersBiomarkers predictive of responseGamma-band powerAssociated with increased theta powerSystematic reviewDissociative classDose of treatmentPredictive of responseClasses of agentsMood disordersBeta and delta bandsMDDAcid diethylamideMechanism of actionBiomarkers predictiveDepressionPatient populationModel of network connectivityResearch vistasNeuropsychological Assessments of Cognitive Impairment in Major Depressive Disorder: A Systematic Review and Meta-Analysis with Meta-Regression
Rhee T, Shim S, Manning K, Tennen H, Kaster T, d’Andrea G, Forester B, Nierenberg A, McIntyre R, Steffens D. Neuropsychological Assessments of Cognitive Impairment in Major Depressive Disorder: A Systematic Review and Meta-Analysis with Meta-Regression. Psychotherapy And Psychosomatics 2024, 93: 8-23. PMID: 38272009, PMCID: PMC10880806, DOI: 10.1159/000535665.Peer-Reviewed Original ResearchConceptsCambridge Neuropsychological Test Automated BatteryAssessment of cognitive impairmentCognitive deficitsCognitive impairmentDepressive disorderNeuropsychological assessmentRemediation of cognitive impairmentAlleviation of depressive symptomsHealthy controlsEffect sizeTreatment-resistant depressionMajor depressive disorderDiagnosis of MDDModerate cognitive deficitsUnmedicated patientsHedges g standardized mean differencesDepressive symptomsMDDCompared to healthy controlsCognitive dysfunctionStandardized effect sizeStandardized diagnostic criteriaQuantify effect sizesDeficitsFixed- or random-effects model
2023
Cognitive behavioral therapy following esketamine for major depression and suicidal ideation for relapse prevention: The CBT-ENDURE randomized clinical trial study protocol
Kitay B, Murphy E, Macaluso M, Corlett P, Hershenberg R, Joormann J, Martinez-Kaigi V, Nikayin S, Rhee T, Sanacora G, Shelton R, Thase M, Wilkinson S. Cognitive behavioral therapy following esketamine for major depression and suicidal ideation for relapse prevention: The CBT-ENDURE randomized clinical trial study protocol. Psychiatry Research 2023, 330: 115585. PMID: 37935086, DOI: 10.1016/j.psychres.2023.115585.Peer-Reviewed Original ResearchMeSH KeywordsCognitive Behavioral TherapyDepressionDepressive Disorder, MajorHumansRandomized Controlled Trials as TopicSuicidal IdeationConceptsCognitive behavioral therapyMajor depressionSuicidal ideationRelapse preventionBehavioral therapyStudy protocolHigh riskClinical trial study protocolLong-term treatment approachKey secondary outcomesTrial study protocolHigh relapse rateHigh-risk populationSignificant suicidal ideationHospital dischargeSecondary outcomesPrimary outcomeRelapse rateFeasibility trialEsketamineTreatment approachesPatientsSuicide attemptsTherapySupplemental indicationsA narrative review of non-racemic amisulpride (SEP-4199) for treatment of depressive symptoms in bipolar disorder and LB-102 for treatment of schizophrenia
Wu J, Kwan A, Rhee T, Ho R, d’Andrea G, Martinotti G, Teopiz K, Ceban F, McIntyre R. A narrative review of non-racemic amisulpride (SEP-4199) for treatment of depressive symptoms in bipolar disorder and LB-102 for treatment of schizophrenia. Expert Review Of Clinical Pharmacology 2023, 16: 1085-1092. PMID: 37864424, DOI: 10.1080/17512433.2023.2274538.Peer-Reviewed Original ResearchMeSH KeywordsAmisulprideAntidepressive AgentsAntipsychotic AgentsBipolar DisorderDepressionDepressive Disorder, MajorHumansSchizophreniaSulpirideConceptsDepressive symptomsSide effectsBipolar disorderRecent phase 2 trialsPhase 2 trialPhase 1 studyTreatment-resistant schizophreniaExtrapyramidal side effectsD2 receptor bindingReceptor-mediated effectsTreatment of schizophreniaMajor depressive disorderImproved treatment strategiesBipolar disorder IDevelopment of SEPAntidepressant effectsDepressive disorderTreatment strategiesPharmacological profileLow dosesNarrative reviewDisorder ISymptomsAmisulprideReceptor bindingDextromethorphan-Bupropion for the Treatment of Depression: A Systematic Review of Efficacy and Safety in Clinical Trials
Akbar D, Rhee T, Ceban F, Ho R, Teopiz K, Cao B, Subramaniapillai M, Kwan A, Rosenblat J, McIntyre R. Dextromethorphan-Bupropion for the Treatment of Depression: A Systematic Review of Efficacy and Safety in Clinical Trials. CNS Drugs 2023, 37: 867-881. PMID: 37792265, DOI: 10.1007/s40263-023-01032-5.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntidepressive AgentsBupropionClinical Trials as TopicDepressionDepressive Disorder, MajorDextromethorphanHumansConceptsMajor depressive disorderPathophysiology of MDDSystematic reviewMontgomery-Åsberg Depression Rating ScaleNMDA receptor antagonist dextromethorphanTransient adverse eventsRisk of biasDepression Rating ScaleMonoamine-based antidepressantsTreatment of depressionBackgroundA significant proportionPlacebo control groupCombination of dextromethorphanMechanism of actionConclusionCurrent evidenceClinical remissionAdverse eventsCochrane riskBias toolDatabase inceptionTreatment optionsScore reductionClinical trialsDepressive disorderActive control groupClinical efficacy and safety of Zuranolone (SAGE-217) in individuals with major depressive disorder
Meshkat S, Teopiz K, Di Vincenzo J, Bailey J, Rosenblat J, Ho R, Rhee T, Ceban F, Kwan A, Cao B, McIntyre R. Clinical efficacy and safety of Zuranolone (SAGE-217) in individuals with major depressive disorder. Journal Of Affective Disorders 2023, 340: 893-898. PMID: 37557991, DOI: 10.1016/j.jad.2023.08.027.Peer-Reviewed Original ResearchMeSH KeywordsAntidepressive AgentsDepressive Disorder, MajorFemaleHumansPregnanesReceptors, GABA-ATreatment OutcomeConceptsMajor depressive disorderAntidepressant effectsGamma-aminobutyric acidDepressive disorderAdverse eventsTreatment-emergent adverse eventsFuture research vistasSerious adverse eventsGABAA receptor expressionEtiology of MDDExtrasynaptic GABAA receptorsCommon mental disordersPositive allosteric modulatorsNeuroactive steroidsClinical efficacyTreatment courseInhibitory GABAergicClinical trialsPostpartum depressionZuranoloneGABAA receptorsReceptor expressionTreatment approachesMental disordersAllosteric modulatorsRising Rates of Suicidal Behaviors and Large Unmet Treatment Needs Among US Adults With a Major Depressive Episode, 2009 to 2020
Bommersbach T, Rosenheck R, Rhee T. Rising Rates of Suicidal Behaviors and Large Unmet Treatment Needs Among US Adults With a Major Depressive Episode, 2009 to 2020. Mayo Clinic Proceedings 2023, 98: 969-984. PMID: 37419587, DOI: 10.1016/j.mayocp.2023.02.012.Peer-Reviewed Original ResearchMeSH KeywordsCOVID-19Depressive Disorder, MajorHumansSubstance-Related DisordersSuicidal IdeationSuicide, AttemptedYoung AdultConceptsMajor depressive episodePast-year major depressive episodeMental health service useMultivariable-adjusted analysesHealth service usePast-year suicidal ideationSubstance use disordersSuicidal ideationSuicide attemptsUse disordersOdds ratioService useUnmet treatment needCoronavirus disease 2019 (COVID-19) pandemicMental health servicesMental health treatmentAlcohol use disorderDisease 2019 pandemicRates of SIHispanic patientsUnmet treatmentDepressive episodeUnadjusted proportionTreatment needsUS adultsLived Experience–Led Research Agenda to Address Early Death in People With a Diagnosis of a Serious Mental Illness
Fortuna K, Lebby S, Geiger P, Johnson D, MacDonald S, Chefetz I, Ferron J, St George L, Rossom R, Kalisa J, Mestrovic T, Nicholson J, Pringle W, Rotondi A, Sippel L, Sica A, Solesio M, Wright M, Zisman-Ilani Y, Gambee D, Hill J, Brundrett A, Cather C, Rhee T, Daumit G, Angel J, Manion I, Deegan P, Butler J, Pitts N, Brodey D, Williams A, Parks J, Reimann B, Wahrenberger J, Morgan O, Bradford D, Bright N, Stafford E, Bohm A, Carney T, Haragirimana C, Gold A, Storm M, Walker R. Lived Experience–Led Research Agenda to Address Early Death in People With a Diagnosis of a Serious Mental Illness. JAMA Network Open 2023, 6: e2315479. PMID: 37234010, DOI: 10.1001/jamanetworkopen.2023.15479.Peer-Reviewed Original ResearchMeSH KeywordsBipolar DisorderConsensusDepressive Disorder, MajorHumansMental DisordersMental HealthSchizophreniaConceptsSerious mental illnessEarly mortalityMental illnessMajor depressive disorderCo-occurring disordersCaregivers of peopleExpert group consensusSchizophrenia spectrum disordersPeer support specialistsSMI diagnosisMedication useDepressive disorderRecovery coachesEarly deathGeneral populationHealth literacySupport cliniciansBipolar disorderSubstance misuseMortalityDiagnostic accuracyMental healthDiagnosisDisordersPrecision medicine
2022
Biomarkers of ketamine's antidepressant effect: An umbrella review
Meshkat S, Ho R, Cao B, Teopiz K, Rosenblat J, Rhee T, Di Vincenzo J, Ceban F, Jawad M, McIntyre R. Biomarkers of ketamine's antidepressant effect: An umbrella review. Journal Of Affective Disorders 2022, 323: 598-606. PMID: 36521662, DOI: 10.1016/j.jad.2022.12.021.Peer-Reviewed Original ResearchConceptsKetamine's antidepressant effectsAntidepressant effectsUmbrella reviewMajor depressive disorder (MDD) pathogenesisRapid acting antidepressant (RAAD) effectsMechanistically relevant biomarkersPotential peripheral biomarkerTreatment-resistant patientsAnti-inflammatory effectsNMDA receptor antagonistReal-world populationTreatment response predictionInflammatory markersPeripheral biomarkersKetamine actionReceptor antagonistSymptom deteriorationClinical utilityNeuroimaging biomarkersDisorder pathogenesisSynaptic plasticityCingulate cortexSystematic reviewKetamineFunctional connectivityEfficacy and Safety of Ketamine vs Electroconvulsive Therapy Among Patients With Major Depressive Episode
Rhee TG, Shim SR, Forester BP, Nierenberg AA, McIntyre RS, Papakostas GI, Krystal JH, Sanacora G, Wilkinson ST. Efficacy and Safety of Ketamine vs Electroconvulsive Therapy Among Patients With Major Depressive Episode. JAMA Psychiatry 2022, 79: 1162-1172. PMID: 36260324, PMCID: PMC9582972, DOI: 10.1001/jamapsychiatry.2022.3352.Peer-Reviewed Original ResearchMeSH KeywordsDepressive Disorder, MajorElectroconvulsive TherapyHumansKetamineRandomized Controlled Trials as TopicSuicide, AttemptedConceptsStandardized mean differenceMajor depressive episodeSerious adverse eventsElectroconvulsive therapyAdverse eventsDepressive episodeClinical trialsDepression severityEfficacy outcomesSystematic reviewUnique adverse effect profileMeta-analyses (PRISMA) reporting guidelinesSafety of ketamineAdverse effect profileData extractionEuropean clinical trialsDiagnosis of depressionModerate methodological qualityMedical Subject Headings termsPreferred Reporting ItemsCognition/memoryRandom-effects modelSubject Headings termsAcute phaseEffect profileNational Trends of Mental Health Care Among US Adults Who Attempted Suicide in the Past 12 Months
Bommersbach TJ, Rosenheck RA, Rhee TG. National Trends of Mental Health Care Among US Adults Who Attempted Suicide in the Past 12 Months. JAMA Psychiatry 2022, 79: 219-231. PMID: 35044428, PMCID: PMC8771432, DOI: 10.1001/jamapsychiatry.2021.3958.Peer-Reviewed Original ResearchMeSH KeywordsCross-Sectional StudiesDepressive Disorder, MajorFemaleHumansMental HealthRisk FactorsSuicide, AttemptedYoung AdultConceptsMental health servicesPast-year useSuicide attemptsClinical factorsRisk factorsUS adultsHealth servicesMultivariate-adjusted logistic regression analysisPast-year suicide attemptsRepresentative cross-sectional studyStudy periodMajor depressive episodeNon-Hispanic white individualsStrong risk factorCross-sectional studyLogistic regression analysisSerious psychological distressNational trendsMental health careAlcohol use disorderSuicide attempt ratesOverall annual rateDepressive episodeSignificant changesSubgroup analysis
2021
Cognitive Behavioral Therapy to Sustain the Antidepressant Effects of Ketamine in Treatment-Resistant Depression: A Randomized Clinical Trial
Wilkinson ST, Rhee TG, Joormann J, Webler R, Ortiz Lopez M, Kitay B, Fasula M, Elder C, Fenton L, Sanacora G. Cognitive Behavioral Therapy to Sustain the Antidepressant Effects of Ketamine in Treatment-Resistant Depression: A Randomized Clinical Trial. Psychotherapy And Psychosomatics 2021, 90: 318-327. PMID: 34186531, DOI: 10.1159/000517074.Peer-Reviewed Original ResearchMeSH KeywordsAntidepressive AgentsCognitive Behavioral TherapyDepressionDepressive Disorder, MajorDepressive Disorder, Treatment-ResistantHumansKetamineTreatment OutcomeConceptsTreatment-resistant depressionCognitive behavioral therapyAntidepressant effectsClinical trialsMontgomery-Asberg Depression Rating ScaleBehavioral therapyGreater sustained improvementsRapid-acting antidepressantsSubset of patientsDepression Rating ScaleTime interaction effectsEffect sizeKetamine respondersClinical responseIntravenous ketamineIntravenous infusionQuick InventoryOngoing treatmentSustained improvementCBT groupTreatment approachesLong-term exposureLarge effect sizesDepressive symptomatologyKetamineBarriers to the Implementation of Electroconvulsive Therapy (ECT): Results From a Nationwide Survey of ECT Practitioners
Wilkinson ST, Kitay BM, Harper A, Rhee TG, Sint K, Ghosh A, Lopez MO, Saenz S, Tsai J. Barriers to the Implementation of Electroconvulsive Therapy (ECT): Results From a Nationwide Survey of ECT Practitioners. Psychiatric Services 2021, 72: 752-757. PMID: 33971727, DOI: 10.1176/appi.ps.202000387.Peer-Reviewed Original ResearchMeSH KeywordsAgedDepressive Disorder, MajorElectroconvulsive TherapyHumansMedicareNew EnglandSurveys and QuestionnairesUnited States
2020
Stages of major depressive disorder and behavioral multi-morbidities: Findings from nationally representative epidemiologic study
Rhee TG, Mohamed S, Rosenheck RA. Stages of major depressive disorder and behavioral multi-morbidities: Findings from nationally representative epidemiologic study. Journal Of Affective Disorders 2020, 278: 443-452. PMID: 33010569, DOI: 10.1016/j.jad.2020.09.081.Peer-Reviewed Original ResearchMeSH KeywordsAdultComorbidityCross-Sectional StudiesDepressive Disorder, MajorDiagnostic and Statistical Manual of Mental DisordersEpidemiologic StudiesHumansMorbidityConceptsChronic major depressive disorderMajor depressive disorderNew-onset major depressive disorderOnset major depressive disorderBorderline personality disorderDepressive disorderUse disordersRepresentative cross-sectional surveyRepresentative epidemiologic studyPersonality disorderMore psychiatric disordersSubstance use disordersAlcohol use disorderNational Epidemiologic SurveyRelated Conditions-IIICross-sectional surveyDSM-5 diagnostic criteriaMultivariable analysisGroup of adultsEpidemiologic studiesUS adultsDiagnostic criteriaPsychiatric disordersEpidemiologic SurveyMDD historyMajor depressive disorder and impaired health‐related quality of life among US older adults
Rhee TG, Steffens DC. Major depressive disorder and impaired health‐related quality of life among US older adults. International Journal Of Geriatric Psychiatry 2020, 35: 1189-1197. PMID: 32497391, DOI: 10.1002/gps.5356.Peer-Reviewed Original ResearchMeSH KeywordsAgedComorbidityCross-Sectional StudiesDepressive Disorder, MajorHumansQuality of LifeSurveys and QuestionnairesConceptsPast major depressive disorderCurrent major depressive disorderMajor depressive disorderMental component summaryHealth-related qualityPhysical component summaryQuality-adjusted life yearsHRQOL measuresOlder adultsComponent summaryDepressive disorderMultivariable-adjusted linear regressionCurrent MDD groupLifetime major depressive disorderRelated Conditions Wave IIIHealth Interview SurveyHistory of MDDUS older adultsNational Epidemiological SurveyCross-sectional analysisDSM-5 criteriaLower HRQoLResidual impairmentWave IIIEpidemiological surveyCharacterization of the Quality of Electroconvulsive Therapy Among Older Medicare Beneficiaries.
Rhee TG, Olfson M, Sint K, Wilkinson ST. Characterization of the Quality of Electroconvulsive Therapy Among Older Medicare Beneficiaries. The Journal Of Clinical Psychiatry 2020, 81 PMID: 32659875, DOI: 10.4088/jcp.19m13186.Peer-Reviewed Original ResearchConceptsElectroconvulsive therapyMedicare beneficiariesECT treatmentElderly individualsMaintenance courseRecipients of ECTMore ECT sessionsReceipt of psychotherapyProportion of patientsTreatment-resistant depressionOlder Medicare beneficiariesElderly Medicare beneficiariesMajor depressive disorderSubtherapeutic courseECT sessionsElderly patientsTreatment patternsImportant therapyDepressive disorderAdequate courseClinical measuresProportion of individualsGeneral populationTotal treatmentTherapy
2018
Antipsychotic Prescriptions Among Adults With Major Depressive Disorder in Office-Based Outpatient Settings: National Trends From 2006 to 2015.
Rhee TG, Mohamed S, Rosenheck RA. Antipsychotic Prescriptions Among Adults With Major Depressive Disorder in Office-Based Outpatient Settings: National Trends From 2006 to 2015. The Journal Of Clinical Psychiatry 2018, 79: 17m11970. PMID: 29469245, PMCID: PMC5932223, DOI: 10.4088/jcp.17m11970.Peer-Reviewed Original ResearchConceptsMajor depressive disorderAntipsychotic prescribingAntipsychotic prescriptionsDepressive disorderNational Ambulatory Medical Care SurveyOffice-based outpatient visitsAmbulatory Medical Care SurveyMultivariable logistic regression analysisMore concomitant medicationsNext-step therapyNext-step treatmentsAdults 75 yearsLogistic regression analysisLong-term effectivenessGreater long-term effectivenessConcomitant medicationsClinical factorsAntipsychotic useOutpatient visitsAntipsychotic treatmentOutpatient settingCare SurveyMental health counselingAntipsychotic agentsDiagnosis of cannabis